Form 4: Arrowhead Pharmaceuticals CFO Sells Shares Following RSU Vesting

Arrowhead Pharmaceuticals' Chief Financial Officer, Kenneth Myszkowski, sold a portion of his shares to cover tax obligations after receiving restricted stock units.

Summary

• Kenneth Myszkowski, the Chief Financial Officer of Arrowhead Pharmaceuticals, received 100,000 shares of common stock on January 4, 2025, as part of a restricted stock unit grant that vests annually over four years.
• On January 6 and 7, 2025, Mr. Myszkowski sold a total of 45,167 shares of common stock at prices ranging from $19.18 to $20.20 per share.
• These sales were conducted under a pre-arranged 10b5-1 trading plan and included shares sold to cover tax withholding obligations related to the vesting of the restricted stock units.
• Following these transactions, Mr. Myszkowski directly owns 455,433 shares of Arrowhead Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (executive stock sale under a 10b5-1 plan) which is neither particularly positive nor negative. The sale is likely for tax purposes and does not indicate a lack of confidence in the company.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which is a common practice for executives to avoid accusations of insider trading.
• The vesting of restricted stock units indicates a form of compensation and alignment with the company's long-term performance.

Negatives

• The sale of shares by a high-ranking executive could be perceived negatively by some investors, although it is a common practice for tax obligations.

Risks

• Executive stock sales, even under a 10b5-1 plan, can sometimes create short-term price volatility.
• There is a risk that further sales by the CFO could put downward pressure on the stock price.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, particularly after the vesting of stock options or restricted stock units. This activity is often part of a pre-planned strategy to manage personal finances and tax obligations.

Comparison to Industry Standards

• Many executives in the pharmaceutical and biotech industries use 10b5-1 trading plans to manage their stock sales, similar to Mr. Myszkowski.
• The sale of shares to cover tax obligations is a standard practice, and the volume of shares sold is not unusual for a CFO of a company of Arrowhead's size.
• Companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals, which are also in the RNAi therapeutics space, often see similar executive stock transactions.

Stakeholder Impact

• Shareholders may have a neutral reaction to the news, as the sales were part of a pre-planned strategy and for tax purposes.
• Employees may see this as a normal part of executive compensation.

Key Dates

Keywords

Arrowhead Pharmaceuticals, Kenneth Myszkowski, CFO, stock sale, restricted stock units, 10b5-1 trading plan, insider trading, tax obligations